Trulieve Cannabis
Market Cap
CA$3.0b
Last Updated
2020/08/08 00:12 UTC
Data Sources
Company Financials +
Executive Summary
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company.
Rewards
Risk Analysis
Snowflake Analysis
Exceptional growth potential and undervalued.
Similar Companies
Share Price & News
How has Trulieve Cannabis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TRUL's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
16.3%
TRUL
-0.2%
CA Pharmaceuticals
2.5%
CA Market
1 Year Return
107.8%
TRUL
-49.0%
CA Pharmaceuticals
-3.9%
CA Market
Return vs Industry: TRUL exceeded the Canadian Pharmaceuticals industry which returned -48.6% over the past year.
Return vs Market: TRUL exceeded the Canadian Market which returned -4.1% over the past year.
Shareholder returns
| TRUL | Industry | Market | |
|---|---|---|---|
| 7 Day | 16.3% | -0.2% | 2.5% |
| 30 Day | 46.1% | 16.4% | 7.0% |
| 90 Day | 73.2% | 30.6% | 11.4% |
| 1 Year | 107.8%107.8% | -49.0%-49.0% | -0.5%-3.9% |
| 3 Year | n/a | 4.8%3.9% | 12.6%1.8% |
| 5 Year | n/a | 284.1%284.1% | 33.8%13.4% |
Price Volatility Vs. Market
How volatile is Trulieve Cannabis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Is Now The Time To Put Trulieve Cannabis (CSE:TRUL) On Your Watchlist?3 weeks ago | Simply Wall St
Can You Imagine How Trulieve Cannabis' (CSE:TRUL) Shareholders Feel About The 47% Share Price Increase?2 months ago | Simply Wall St
How Does Trulieve Cannabis's (CSE:TRUL) P/E Compare To Its Industry, After Its Big Share Price Gain?Valuation
Is Trulieve Cannabis undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TRUL (CA$25.18) is trading below our estimate of fair value (CA$110.31)
Significantly Below Fair Value: TRUL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TRUL is good value based on its PE Ratio (11.7x) compared to the CA Pharmaceuticals industry average (12.3x).
PE vs Market: TRUL is good value based on its PE Ratio (11.7x) compared to the Canadian market (15.5x).
Price to Earnings Growth Ratio
PEG Ratio: TRUL is good value based on its PEG Ratio (0.4x)
Price to Book Ratio
PB vs Industry: TRUL is overvalued based on its PB Ratio (7x) compared to the CA Pharmaceuticals industry average (1.4x).
Next Steps
Future Growth
How is Trulieve Cannabis forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
30.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRUL's forecast earnings growth (30.7% per year) is above the savings rate (1.7%).
Earnings vs Market: TRUL's earnings (30.7% per year) are forecast to grow faster than the Canadian market (24.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: TRUL's revenue (26.8% per year) is forecast to grow faster than the Canadian market (5.7% per year).
High Growth Revenue: TRUL's revenue (26.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TRUL's Return on Equity is forecast to be high in 3 years time (20.6%)
Next Steps
Past Performance
How has Trulieve Cannabis performed over the past 5 years?
97.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TRUL has a high level of non-cash earnings.
Growing Profit Margin: TRUL's current net profit margins (58.3%) are higher than last year (27.6%).
Past Earnings Growth Analysis
Earnings Trend: TRUL's earnings have grown significantly by 97.5% per year over the past 5 years.
Accelerating Growth: TRUL's earnings growth over the past year (385.9%) exceeds its 5-year average (97.5% per year).
Earnings vs Industry: TRUL earnings growth over the past year (385.9%) exceeded the Pharmaceuticals industry -12.4%.
Return on Equity
High ROE: TRUL's Return on Equity (59.6%) is considered outstanding.
Next Steps
Financial Health
How is Trulieve Cannabis's financial position?
Financial Position Analysis
Short Term Liabilities: TRUL's short term assets ($384.5M) exceed its short term liabilities ($73.6M).
Long Term Liabilities: TRUL's short term assets ($384.5M) exceed its long term liabilities ($269.0M).
Debt to Equity History and Analysis
Debt Level: TRUL's debt to equity ratio (44.9%) is considered high.
Reducing Debt: Insufficient data to determine if TRUL's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: TRUL's debt is well covered by operating cash flow (28.3%).
Interest Coverage: TRUL's interest payments on its debt are well covered by EBIT (15.7x coverage).
Balance Sheet
Next Steps
Dividend
What is Trulieve Cannabis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TRUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TRUL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TRUL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TRUL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TRUL's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.1yrs
Average management tenure
CEO
Kim Rivers (42 yo)
1.92yrs
Tenure
US$443,750
Compensation
Ms. Kimberly Rivers, also known as Kim, serves as Chairman of Trulieve Cannabis Corp. and has been its Chief Executive Officer and Director since September 2018 and November 2015 respectively. Ms. Rivers i ...
CEO Compensation Analysis
Compensation vs Market: Kim's total compensation ($USD443.75K) is below average for companies of similar size in the Canadian market ($USD2.03M).
Compensation vs Earnings: Kim's compensation has increased by more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.92yrs | US$443.75k | 15.04% $ 446.9m | |
| Chief Information Officer | 1.92yrs | US$182.50k | no data | |
| General Counsel & Corporate Secretary | 1.5yrs | US$209.17k | no data | |
| Chief Production Officer | 0.83yr | US$653.36k | 0.0077% $ 227.9k | |
| Chief Financial Officer | 0.17yr | no data | no data | |
| Director of Investor Relations & Corporate Communications | 1.42yrs | no data | no data | |
| Director of Marketing & Community Relations | no data | no data | no data | |
| Chief Sales Officer | 0.83yr | no data | no data | |
| Chief Marketing Officer | 0.67yr | no data | no data | |
| Director of Human Resources | 2.75yrs | no data | 0.0077% $ 227.9k | |
| Chief of Staff | 0.083yr | no data | no data | |
| Controller & Director of Financial Reporting | no data | no data | no data |
1.1yrs
Average Tenure
47yo
Average Age
Experienced Management: TRUL's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.92yrs | US$443.75k | 15.04% $ 446.9m | |
| Director | 1.08yrs | no data | no data | |
| Director | 0.17yr | no data | no data | |
| Director | 0.17yr | no data | no data | |
| Independent Director | 4.75yrs | no data | 13.53% $ 402.0m | |
| Independent Director | 4.75yrs | no data | no data | |
| Independent Director | 4.75yrs | no data | no data | |
| Independent Director | 2.17yrs | no data | no data |
2.2yrs
Average Tenure
61.5yo
Average Age
Experienced Board: TRUL's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.
Top Shareholders
Company Information
Trulieve Cannabis Corp.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Trulieve Cannabis Corp.
- Ticker: TRUL
- Exchange: CNSX
- Founded:
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$2.971b
- Shares outstanding: 113.07m
- Website: https://www.trulieve.com
Number of Employees
Location
- Trulieve Cannabis Corp.
- 6749 Ben Bostic Road
- Quincy
- Florida
- 32351
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TRUL | CNSX (Canadian National Stock Exchange) | Yes | Subordinate Votings Shares | CA | CAD | Sep 2018 |
| TCNN.F | OTCPK (Pink Sheets LLC) | Yes | Subordinate Votings Shares | US | USD | Sep 2018 |
Biography
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded store ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/08/08 00:12 |
| End of Day Share Price | 2020/08/07 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.